acetaminophen, IV preparation — Competitive Intelligence Brief

acetaminophen, IV preparation (acetaminophen, IV preparation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic and antipyretic. Area: Pain Management, Fever.

marketed Analgesic and antipyretic Cyclooxygenase (COX), primarily central nervous system isoforms Pain Management, Fever Small molecule

Target snapshot

acetaminophen, IV preparation (acetaminophen, IV preparation) — The University of Texas Health Science Center at San Antonio. Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
acetaminophen, IV preparation TARGET	acetaminophen, IV preparation	The University of Texas Health Science Center at San Antonio	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen (paracetamol)	Acetaminophen (paracetamol)	Hellenic Society of Hematology	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen IV/PO	Acetaminophen IV/PO	The University of Texas Health Science Center, Houston	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes; possibly TRPV1 and other pain pathways
acetaminophen IV	acetaminophen IV	Nantes University Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes
Panadol®	Panadol®	Sinew Pharma Inc.	marketed	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX), primarily in central nervous system
Acetaminophen Injection	Acetaminophen Injection	Mount Sinai Hospital, Canada	marketed	Analgesic and antipyretic	Cyclooxygenase (COX)
IV Acetaminophen (Treatment A)	IV Acetaminophen (Treatment A)	Mallinckrodt	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic and antipyretic class)

1. Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · 2 drugs in this class
2. Mallinckrodt · 2 drugs in this class
3. The University of Texas Health Science Center, Houston · 2 drugs in this class
4. Hellenic Society of Hematology · 1 drug in this class
5. John van den Anker · 1 drug in this class
6. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
7. Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 drug in this class
8. Merck Sharp & Dohme LLC · 1 drug in this class
9. Mount Sinai Hospital, Canada · 1 drug in this class
10. Nantes University Hospital · 1 drug in this class